Bayer

CRO Evotec sees spin-out firm as strategic opportunity

Image: iStock/ArielMieli

Evotec’s auto-immune spin-out Topas represents “a strategic opportunity” for the CRO, which reported strong first quarter sales this week.

PCT Europe took place in Hamburg, Germany

Patient-centric trials to give CROs competitive edge, say sponsors

German CRO joins tenants on Bayer campus

German CRO joins tenants on Bayer campus

Brian Cass, Huntingdon CEO

Preclinical prices improving says Huntingdon CEO; firm is mulling US capacity expansion

The CoLaborator project is based in San Francisco, California. (Image: Evonne)

Bayer manufactures for biologics start-up in CoLaborator project

PPD's X-Chem is signing a number of deals with Big Pharma

PPD’s X-Chem signs multi-target collaboration with Janssen

Evotec has had a breakthrough year in 2014

European CRO Evotec cashes in on strategic partnerships

PPD’s X-Chem licenses cardiovascular drug discovery program to Bayer

PPD’s X-Chem licenses cardiovascular drug discovery program to Bayer

Covance calls investor suit seeking to derail acquisition meritless

Covance says investor lawsuit seeking to derail LabCorp acquisition ‘without merit’

Speedy

Mercks & recreation? The pharma industry and the sporting world

More Bayer